Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats

Oligonucleotides

Volumn 16, Issue 3, 2006, Pages 203-212

  Fortin, Marylène ^a   Ferrari, Nicolay ^a   Higgins, Marie Ève ^a   Séguin, Serge ^a,b   Allam, Mustapha ^b   Allakhverdi, Zoulfia ^b   Piaget Rodriguez, Carmen ^b   Paquet, Luc ^a   Renzi, Paolo M ^a,b,c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE 4; CHEMOKINE; CHEMOKINE RECEPTOR CCR3; EOTAXIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OVALBUMIN; UNCLASSIFIED DRUG;

AIRWAY; AIRWAY HYPERRESPONSIVENESS; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; EOSINOPHIL; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; LOEFFLER PNEUMONIA; LUNG PARENCHYMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; RAT STRAIN; RECEPTOR BINDING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; OLIGONUCLEOTIDES, ANTISENSE; OVALBUMIN; PERITONITIS; RATS; RATS, INBRED BN; RECEPTORS, CHEMOKINE; RNA, MESSENGER;

RATTUS NORVEGICUS;

EID: 33751094071     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.16.203     Document Type: Article

References (49)

1. ALLAKHVERDI, Z., LAMKHIOUED, B., OLIVENSTEIN, R., HAMID, Q., and RENZI, P.M. (2000). CD8 depletion-induced late airway response is characterized by eosinophilia, increased eotaxin, and decreased IFN-γ expression in rats. Am. J. Respir. Crit. Care Med. 162, 1123-1131.
2. ALLAKHVERDI, Z., ALLAM, M., and RENZI, P.M. (2002). Inhibition of antigen-induced eosinophilia and AHR by antisense oligonucleotides directed against the common β chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am. J. Respir. Crit. Care Med. 165, 1015-1021.
3. BAGGIOLINI, M., DEWALD, B., and MOSER, B. (1997). Human chemokines: An update. Annu. Rev. Immunol. 15, 675-705.
4. BANNER, K.H., PAUL, W., and PAGE, C.P. (1996). Ovalbumin challenge following immunization elicits recruitment of eosinophils but not bronchial hyperresponsiveness in guinea-pigs: Time course and relationship to eosinophil activation status. Pulm. Pharmacol. 9, 179-187.
5. BARNES, P.J. (2003). Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 14, 511-522.
6. BERTRAND, C.P., and PONATH, P.D. (2000). CCR3 blockade as a new therapy for asthma. Expert Opin. Investig. Drugs 9, 43-52.
7. CAMERON, L., CHRISTODOULOPOULOS, P., LAVIGNE, F., NAKAMURA, Y., EIDELMAN, D., MCEUEN, A., WALLS, A., TAVERNIER, J. MINSHALL, E., MOQBEL, R., and HAMID, Q. (2000). Evidence for local eosinophil differentiation within allergic nasal mucosa: Inhibition with soluble IL-5 receptor. J. Immunol. 164, 1538-1545.
8. COMBADIERE, C., AHUJA, S.K., and MURPHY, P.M. (1995). Cloning and functional expression of a human eosinophil CC chemokine receptor. J. Biol. Chem. 270, 16491-16494.
9. CROOKE, S.T. (2004). Progress in antisense technology. Annu. Rev. Med. 55, 61-95.
10. DE MONCHY, J.G., KAUFFMAN, H.F., VENGE, P., KOETER, G.H., JANSEN, H.M., SLUITER, H.J., and DE VRIES, K. (1995). Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis. 131, 373-376.
11. EIDELMAN, D.H., MINSHALL, E., DANDURAND, R.J., SCHOTMAN, E., SONG, Y.L., YASRUEL, Z., MOQBEL, R., and HAMID, Q. (1996). Evidence for major basic protein immunoreactivity and interleukin 5 gene activation during the late phase response in explanted airways. Am. J. Respir. Cell Mol. Biol. 15, 582-589.
12. EIDELMAN, D.H., BELLOFIORE, S., and MARTIN, J.G. (1998). Late airway responses to antigen challenge in sensitized inbred rats. Am. Rev. Respir. Dis. 137, 1033-1037.
13. ERIN, E.M., WILLIAMS, T.J., BARNES, P.J., and HANSEL, T.T. (2002). Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr. Drug Targets Inflamm. Allergy 1, 201-214.
14. ERMERT, L., SEEGER, W., and DUNCKER, H.R. (1993). Computer-assisted morphometry of the intracapillary leukocyte pool in the rabbit lung. Cell Tissue Res. 271, 469-476.
15. FUJISAWA, T., KATO, Y., NAGASE, H., ATSUTA, J., TERADA, A., IGUCHI, K., KAMIYA, H., MORITA, Y., KITAURA, M., KAWASAKI, H., YOSHIE, O., and HIRAI, K. (2000). Chemokines induce eosinophil degranulation through CCR-3. J. Allergy Clin. Immunol. 106, 507-513.
16. GAO, W.Y., HAN, F.S., STORM, C., EGAN, W., and CHENG, Y.C. (1992). Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol. Pharmacol. 41, 223-229.
17. GARCIA-ZEPEDA, E.A., ROTHENBERG, M.E., OWNBEY, R.T., CELESTIN, J., LEDER, P., and LUSTER, A.D. (1996). Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat. Med. 2, 449-456.
18. GLEICH, G.J. (1990). The eosinophil and bronchial asthma: Current understanding. J. Allergy Clin. Immunol. 85, 422-436.
19. GONZALO, J.A., LLOYD, C.M., WEN, D., ALBAR, J.P., WELLS, T.N., PROUDFOOT, A., MARTINEZ, A., DORF, M., BJERKE, T., COYLE, A.J., and GUTIERREZ-RAMOS, J.C. (1998). The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188, 157-167.
20. GRIFFITHS-JOHNSON, D.A., COLLINS, P.D., ROSSI, A.G., JOSE, P.J., and WILLIAMS, T.J. (1993). The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem. Biophys. Res. Commun. 197, 1167-1172.
21. GRIMALDI, J.C., YU, N.X., GRUNIG, G., SEYMOUR, B.W., COTTREZ, F., ROBINSON, D.S., HOSKEN, N., FERLIN, W.G., WU, X., SOTO, H., O'GARRA, A., HOWARD, M.C., and COFFMAN, R.L. (1999). Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J. Leukoc. Biol. 65, 846-853.
22. HUMBERT, M., YING, S., CORRIGAN, C., MENZ, G., BARKANS, J., PFISTER, R., MENG, Q., VAN DAMME, J., OPDENAKKER, G., DURHAM, S.R., and KAY, A.B. (1997). Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: Relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony- stimulating factor, and IL-3. Am. J. Respir. Cell Mol. Biol. 16, 1-8.
23. JOSE, P.J., GRIFFITHS-JOHNSON, D.A., COLLINS, P.D., WALSH, D.T., MOQBEL, R., TOTTY, N.F., TRUONG, O., HSUAN, J.J., and WILLIAMS, T.J. (1994). Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med. 179, 881-887.
24. JUSTICE, J.P., BORCHERS, M.T., CROSBY, J.R., HINES, E.M., SHEN, H.H., OCHKUR, S.I., McGARRY, M.P., LEE, N.A., and LEE, J.J. (2003). Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am. J. Physiol. Lung Cell Mol. Physiol. 284, L169-L178.
25. KAMPEN, G.T., STAFFORD, S., ADACHI, T., JINQUAN, T., QUAN, S., GRANT, J.A., SKOV, P.S., POULSEN, L.K., and ALAM, R. (2000). Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95, 1911-1917.
26. LAMKHIOUED, B., RENZI, P.M., ABI-YOUNES, S., GARCIA-ZEPADA, E.A., ALLAKHVERDI, Z., GHAFFAR, O., ROTHENBERG, M.D., LUSTER, A.D., and HAMID, Q. (1997). Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J. Immunol. 159, 4593-4601.
27. + progenitor cells. J. Immunol. 170, 537-547.
28. MA, W., BRYCE, P.J., HUMBLES, A.A., LAOUINI, D., YALCINDAG, A., ALENIUS, H., FRIEND, D.S., OETTGEN, H.C., GERARD, C., and GEHA, R.S. (2002). CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J. Clin. Invest. 109, 621-628.
29. MARTIN, G.J., SUZUKI, M., RAMOS-BARBON, D., and ISOGAl, S. (2004). T cell cytokines: Animal models. Paediatr. Respir. Rev. 5, S47-S51.
30. MOHRI, H., MOTOMURA, S., and OKUBO, T. (1998). Unusual leukocytosis with eosinophilia by an allergic disease. Am. J. Hematol. 57, 90-91.
31. OWEN, C. (2001). Chemokine receptors in airway disease: Which receptors to target? Pulm. Pharmacol. Ther. 14, 193-202.
32. PALFRAMAN, R.T., COLLINS, P.D., WILLIAMS, T.J., and RANKIN, S.M. (1998). Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 91, 2240-2248.
33. PONATH, P.D., QIN, S., RINGLER, D.J., CLARK-LEWIS, I., WANG, J., KASSAM, N., SMITH, H., SHI, X., GONZALO, J.A., NEWMAN, W., GUTIERREZ-RAMOS, J.C., and MACKAY, C.R. (1996). Cloning of the human eosinophil chemoattractant, eotaxin: Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J. Clin. Invest. 97, 604-612.
34. POPE, S.M., ZIMMERMANN, N., STRINGER, K.F., KAROW, K.L., and ROTHENBERG, M.E. (2005). The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J. Immunol. 175, 5341-5350.
35. RENZI, P.M., SAPIENZA, S., WASERMAN, S., DU, T., OLIVENSTEIN, R., WANG, N.S., and MARTIN, J.G. (1992). Effect of interleukin-2 on the airway response to antigen in the rat. Am. Rev. Respir. Dis. 146, 163-169.
36. RENZI, P.M., OLIVENSTEIN, R., and MARTIN, J.G. (1993). Inflammatory cell populations in the airways and parenchyma after antigen challenge in the rat. Am. Rev. Respir. 147, 967-974.
37. RENZI, P.M., AL ASSAAD, A.S., YANG, J., YASRUEL, Z., and HAMID, Q. (1996). Cytokine expression in the presence or absence of late airway responses after antigen challenge of sensitized rats. Am. J. Respir. Cell Mol. Biol. 15, 367-373.
38. + cells in the bronchial mucosa in asthma: Potential airway eosinophil progenitors. Am. J. Respir. Cell Mol. Biol. 23, 9-13.
39. ROTHENBERG, M.E., MACLEAN, J.A., PEARLMAN, E., LUSTER, A.D., and LEDER, P. (1997). Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J. Exp. Med. 185, 785-790.
40. SALLUSTO, F., MACKAY, C.R., and LANZAVECCHIA, A. (2000). The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593-620.
41. SAPIENZA, S., DU, T., EIDELMAN, D.H., WANG, N.S., and MARTIN, J.G. (1991). Structural changes in the airways of sensitized Brown Norway rats after antigen challenge. Am. Rev. Respir. Dis. 144, 423-427.
42. SPRY, C.J. (1971). Mechanism of eosinophilia. VI. Eosinophil mobilization. Cell Tissue Kinet. 4, 365-374.
43. STEIN, C.A. (2001). The experimental use of antisense oligonucleotides: A guide for the perplexed. J. Clin. Invest. 108, 641-644.
44. TOMKINSON, A., DUEZ, C., CIESLEWICZ, G., and GELFAND, E.W. (2001). Eotaxin-1-deficient mice develop airway eosinophilia airway hyperresponsiveness. Int. Arch. Allergy Immunol. 126 119-125.
45. WAGNER, R.W. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-335.
46. WALSH, G.M. (1997). Human eosinophils: Their accumulation, activation and fate. Br. J. Haematol. 97, 701-709.
47. YANG, M., HOGAN, S.P., MAHALINGAM, S., POPE, S.M., ZIMMERMANN, N., FULKERSON, P., DENT, L.A., YOUNG, I.G., MATTHAEI, K.I., ROTHENBERG, M.E., and FOSTER, P.S. (2003). Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. J. Allergy Clin. Immunol. 112, 935-943.
48. YANG, Y., LOY, J., RYSECK, R.P., CARRASCO, D., and BRAVO, R. (1998). Antigen-induced eosinophilic lung inflammation develops in mice deficient in chemokine eotaxin. Blood 92, 3912-3923.
49. YING, S., ROBINSON, D.S., MENG, Q., BARATA, L.T., MCEUEN, A.R., BUCKLEY, M.G., WALLS, A.F., ASKENASE, P.W., and KAY, A.B. (1999). C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J. Immunol. 163, 3976-3984.